Every trade that managers of Immutep Limited disclose to ASX is tracked on this page. The company sits in the Health Care sector and is based in Sydney. It was founded in 2001. Over the twelve months to 18 October 2026, 12 filings were filed, from 8 insiders.
Not one of the filings records a straightforward purchase or sale on the market. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
No insider has bought Immutep Limited shares on the open market in the past twelve months.
For context, the typical company on the same exchange (median of 2,527 companies) published 3 filings over the same period, against 12 filings here.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Cytosorbents Corp also feature in our signals. These figures are compiled from regulatory filings published by ASX. They describe what insiders did and are not a recommendation.
Analysts rate Immutep Limited Buy (bullish), based on 3 analysts. Average price target: A$0.11.
FY ended June 2026 · cache
12 of 12 declarations
Immutep Limited is a biopharmaceutical company focused on developing immunotherapy treatments for cancer and other diseases. It is listed on the XASX market.
Purchases our model currently ranks for the recommendations list.
All recommendationsHeadquarters: Sydney · Founded: 2001 · Wikipedia article
Source: Wikidata (CC0).